Jonathan Wolleben
Stock Analyst at JMP Securities
(4.38)
# 333
Out of 4,910 analysts
204
Total ratings
52.63%
Success rate
17.19%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALT Altimmune | Maintains: Market Outperform | $25 → $15 | $4.11 | +264.96% | 13 | Jul 10, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Market Outperform | $19 → $27 | $15.60 | +73.08% | 4 | Jul 8, 2025 | |
| PRQR ProQR Therapeutics | Reiterates: Market Outperform | $8 | $2.26 | +254.77% | 8 | Jun 27, 2025 | |
| RYTM Rhythm Pharmaceuticals | Reiterates: Market Outperform | $84 | $87.35 | -3.84% | 3 | Jun 26, 2025 | |
| DBVT DBV Technologies | Reiterates: Market Outperform | $21 | $9.78 | +114.83% | 15 | Jun 26, 2025 | |
| SKYE Skye Bioscience | Reiterates: Market Outperform | $15 | $4.01 | +274.06% | 3 | Jun 24, 2025 | |
| GPCR Structure Therapeutics | Reiterates: Market Outperform | $89 | $18.27 | +387.14% | 9 | Jun 23, 2025 | |
| AURA Aura Biosciences | Reiterates: Market Outperform | $19 | $7.06 | +169.12% | 9 | May 23, 2025 | |
| CLSD Clearside Biomedical | Reiterates: Market Outperform | $5 | $0.54 | +827.99% | 11 | May 16, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Market Outperform | $74 → $76 | $52.17 | +45.68% | 10 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $443 | $299.17 | +48.08% | 12 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $38 | $13.03 | +191.75% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $61 | $53.74 | +13.51% | 11 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $22 → $19 | $11.91 | +59.53% | 17 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $55 | $20.05 | +174.31% | 11 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $8.55 | +110.53% | 8 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $26 | $6.56 | +296.34% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $92 → $91 | $30.41 | +199.24% | 14 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $2.55 | +252.94% | 8 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $50 | $50.24 | -0.48% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $90 | $92.96 | -3.18% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $141.62 | - | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Accumulate | $420 → $485 | $681.42 | -28.83% | 1 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $48 → $32 | $10.20 | +213.73% | 8 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $25 | $3.75 | +566.67% | 11 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $0.52 | +1,426.72% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $31.49 | -23.79% | 1 | May 12, 2023 |
Altimmune
Jul 10, 2025
Maintains: Market Outperform
Price Target: $25 → $15
Current: $4.11
Upside: +264.96%
KalVista Pharmaceuticals
Jul 8, 2025
Maintains: Market Outperform
Price Target: $19 → $27
Current: $15.60
Upside: +73.08%
ProQR Therapeutics
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $8
Current: $2.26
Upside: +254.77%
Rhythm Pharmaceuticals
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $84
Current: $87.35
Upside: -3.84%
DBV Technologies
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $21
Current: $9.78
Upside: +114.83%
Skye Bioscience
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $4.01
Upside: +274.06%
Structure Therapeutics
Jun 23, 2025
Reiterates: Market Outperform
Price Target: $89
Current: $18.27
Upside: +387.14%
Aura Biosciences
May 23, 2025
Reiterates: Market Outperform
Price Target: $19
Current: $7.06
Upside: +169.12%
Clearside Biomedical
May 16, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $0.54
Upside: +827.99%
Mirum Pharmaceuticals
May 9, 2025
Maintains: Market Outperform
Price Target: $74 → $76
Current: $52.17
Upside: +45.68%
Apr 24, 2025
Reiterates: Market Outperform
Price Target: $443
Current: $299.17
Upside: +48.08%
Apr 10, 2025
Initiates: Market Outperform
Price Target: $38
Current: $13.03
Upside: +191.75%
Mar 10, 2025
Reiterates: Market Outperform
Price Target: $61
Current: $53.74
Upside: +13.51%
Mar 4, 2025
Maintains: Market Outperform
Price Target: $22 → $19
Current: $11.91
Upside: +59.53%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $55
Current: $20.05
Upside: +174.31%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $8.55
Upside: +110.53%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $26
Current: $6.56
Upside: +296.34%
Feb 28, 2025
Maintains: Market Outperform
Price Target: $92 → $91
Current: $30.41
Upside: +199.24%
Dec 19, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $2.55
Upside: +252.94%
Dec 18, 2024
Maintains: Market Outperform
Price Target: $55 → $50
Current: $50.24
Upside: -0.48%
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $90
Current: $92.96
Upside: -3.18%
Dec 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $141.62
Upside: -
Nov 13, 2024
Downgrades: Accumulate
Price Target: $420 → $485
Current: $681.42
Upside: -28.83%
Aug 15, 2024
Maintains: Market Outperform
Price Target: $48 → $32
Current: $10.20
Upside: +213.73%
May 31, 2024
Reiterates: Market Outperform
Price Target: $25
Current: $3.75
Upside: +566.67%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $0.52
Upside: +1,426.72%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $31.49
Upside: -23.79%